Ondine Biomed Regulatory News (OBI)

1 September 2025

Ondine Biomedical Inc. ("Ondine" or the "Company")

Total Voting Rights Correction

Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company, announces a correction to the total voting rights figure stated in the Company's announcement on 28 August 2025. Following Admission on 3 September 2025, the Company's issued and fully paid share capital will consist of 518,366,964 Common Shares, and not 517,566,964 Common Shares, as previously stated.

Total Voting Rights

Following Admission, the Company's issued and fully paid share capital will consist of 518,366,964 Common Shares, all of which carry one voting right per share. The Company does not hold any Common Shares in treasury. Therefore, the total number of Common Shares and voting rights in the Company at this date will be 518,366,964 Common Shares.

This figure may be used from the date of Admission until further notice by Existing Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. 

Capitalized terms used in this announcement have the meanings given to them in the Company's announcements dated 27 August 2025 and 28 August 2025, unless the context provides otherwise.

Enquiries: